Seeking Alpha

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been ...
CURE

Comparable Safety Profiles of IV and Subcutaneous Immunotherapy in Advanced Melanoma

This segment discusses the safety and side effect profiles of intravenous and subcutaneous immunotherapy in advanced melanoma ...
Rutland Herald

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen , for the treatment of adult patients with systemic ...